PLIANT THERAPEUTICS INC
For the period ended Mar 3, 2025. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 3, 2025 · Filed Mar 3, 2025
Use the contents to explore the available documents and sections.
PLRX$0.81-0.7%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Neuromuscular Program
Neuromuscular Program
PLN-101325 for treatment of muscular dystrophies. PLN-101325 is a monoclonal antibody that acts as an allosteric agonist of integrin α7β1, currently in development for treatment of muscular dystrophies. PLN-101325 is Phase 1 ready with clinical trial approval (CTA) open in Australia.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.